PROK
ProKidney Corp.
$1.61
+13.38%
2026-08-21
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Key Fundamentals
Forward P/E
-2.27
EPS (TTM)
$-0.55
ROE
-59.0%
Revenue Growth (YoY)
-32.1%
Profit Margin
0.0%
Debt/Equity
1.58
Beta
1.72
Market Cap
$530.9M
Avg Volume (10D)
1.2M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$2.24
60D Low
$1.30
Avg Volume
1.3M
Latest Close
$1.61
Get breakout alerts for PROK
Sign up for Breakout Scanner to receive daily notifications when PROK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
ProKidney Corp. (PROK) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PROK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PROK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.